HLB Co., Ltd. (028300.KQ)

KRW 70500.0

(-1.26%)

Market Cap (In KRW)

9244.73 Billion

Revenue (In KRW)

42.9 Billion

Net Income (In KRW)

-189.07 Billion

Avg. Volume

2.1 Million

Currency
KRW
Country
Healthcare
Open
-
Prev. Close
-
Day Range
-
Year Range
42000.0-129000.0
PE
-
EPS
-
Beta Value
0.301
ISIN
KR7028300002
CUSIP
-
CIK
-
Shares
-
Earnings Annoncement
-

Company Profile

Sector
Healthcare
Industry
Biotechnology
CEO
Mr. Jung-Min Park
Employee Count
-
Website
https://www.hlbkorea.com
Ipo Date
2008-12-24
Details
HLB Co., Ltd. manufactures pharmaceutical products, and builds ships. It manufactures and sells various types of lifeboats for marine plants, drill ships, and cruise vessels in South Korea. The company offers conventional type lifeboats, free fall type lifeboats, and rescue boats. It also provides marine and yacht engines; hooks; RIB, patrol, fishing, aluminum, and leisure boats; fishery inspection ships; and safety goods, as well as lifeboat and davit inspection and repair services, service engineering training, and spare parts for lifeboats and davits. In addition, the company develops Riboseranib, a targeted anti-cancer agent; and Apilia that is used for the treatment for ovarian cancer. HLB Co., Ltd. was founded in 1975 and is headquartered in Ulsan, South Korea.